{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:17:59Z","timestamp":1774952279900,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.drugalcdep.2021.109092","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:38:11Z","timestamp":1632501491000},"page":"109092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status"],"prefix":"10.1016","volume":"228","author":[{"given":"George","family":"Pro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2299","authenticated-orcid":false,"given":"D. Andrew","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Azari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nickolas","family":"Zaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2021.109092_bib1","unstructured":"Alderks, C., 2017. Trends in the Use of Methadone, Buprenorphine, and Extended-Release Naltrexone at Substance Abuse Treatment Facilities: 2003\u20132015 (Update). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Short Report. Rockville, MD, August 22, 2017."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib2","unstructured":"American Addiction Centers, 2020. History of American Substance Abuse Treatment Centers. US trends in addiction treatment. Retrieved from \u3008\u3008https:\/\/americanaddictioncenters.org\/learn\/us-trends-addiction-treatment\/\u3009\u3009."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib3","series-title":"Changes in the Supply of Physicians with a DEA DATA Waiver to Prescribe Buprenorphine for Opioid Use Disorder. Data Brief #162","author":"Andrilla","year":"2017"},{"issue":"24","key":"10.1016\/j.drugalcdep.2021.109092_bib4","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/jama.2013.278456","article-title":"Changes in testing for Human Immunideficiency Virus, sexualy transmitted infections, and hepatitis C virus in opioid treatment programs","volume":"310","author":"Bachhuber","year":"2013","journal-title":"JAMA"},{"issue":"2060\u20132060","key":"10.1016\/j.drugalcdep.2021.109092_bib5","article-title":"For-profit treatment of opioid addiction","volume":"32","author":"Bachhuber","year":"2013","journal-title":"Health Aff."},{"issue":"5","key":"10.1016\/j.drugalcdep.2021.109092_bib6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MLR.0000000000000121","article-title":"Profiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United States","volume":"52","author":"Bachhuber","year":"2014","journal-title":"Med. Care"},{"issue":"1","key":"10.1016\/j.drugalcdep.2021.109092_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2021.109092_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jsat.2006.07.004","article-title":"Access to treatment-related and support services in methadone treatment programs","volume":"32","author":"Berkman","year":"2007","journal-title":"J. Subst. Abuse Treat"},{"issue":"2","key":"10.1016\/j.drugalcdep.2021.109092_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/add.14487","article-title":"The evolving drug epidemic of prescription opioid injection and its association with HCV transmission among people who inject drugs in Montreal, Canada","volume":"114","author":"Bruneau","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","article-title":"Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program","volume":"75","author":"Butner","year":"2017","journal-title":"J. Subst. Abuse Treat"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib11","unstructured":"Centers for Disease Control and Prevention, 2018a. Hepatitis C Outbreaks in People who Inject Drugs. Centers for Disease Control and Prevention. Division of Viral Hepatitis, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib12","unstructured":"Centers for Disease Control and Prevention, 2018b. Managing HIV and Hepatitis C Outbreaks among People who Inject Drugs: A Guide for State and Local Health Departments. Version 1.0. Division of HIV\/AIDS Prevention. National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib13","unstructured":"Centers for Disease Control and Prevention, 2020a. 2017\u20132018 Drug Overdose Death Rate Increases Map. Centers for Disease Control and Prevention Opioid Overdose. Statistically significant drug overdose death rate increase from 2017 to 2018, US states."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib14","series-title":"Managing Investigations During and Outbreak","year":"2020"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib15","unstructured":"Centers for Disease Control and Prevention, 2020c. Viral Hepatitis Surveillance: United States, 2018. Centers for Disease Control and Prevention Division of Viral Hepatitis. National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB prevention."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib16","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area depriation continua: a US nationwide small area analysis","author":"Des","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib17","unstructured":"Ene, M., Leighton, E., Blue, G., Bell, B., 2015. Multilevel Models for Categorical Data using SAS PROC GLIMMIX: The Basics. SAS Papers Paper 3430\u20132015."},{"issue":"8","key":"10.1016\/j.drugalcdep.2021.109092_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/aje\/kwz097","article-title":"Scaling up hepatitis C prevention and treatment interventions for achieving elimination in the United States: a rural and urban comparison","volume":"188","author":"Fraser","year":"2019","journal-title":"Am. J. Epidemiol"},{"issue":"1","key":"10.1016\/j.drugalcdep.2021.109092_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/add.13948","article-title":"Scaling-up HCV prevention and treatment interventions in rural United States - Model projections for tackling an increasing epidemic","volume":"113","author":"Fraser","year":"2018","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.drugalcdep.2021.109092_bib20","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2105\/AJPH.2013.301827","article-title":"Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study","volume":"104","author":"Frimpong","year":"2014","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib21","series-title":"Population Distribution by Race\/Ethnicity","author":"Henry J. Kaiser Family Foundation","year":"2019"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib22","unstructured":"Henry J. Kaiser Family Foundation, 2019b. State Health Facts. Demographics and the economy. people in poverty. distribution of total population by federal poverty level."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib23","series-title":"Individuals Reporting Past Year Opioid Use Disorder","author":"Henry J. Kaiser Family Foundation","year":"2020"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib24","unstructured":"Henry J. Kaiser Family Foundation, 2020b. Status of State Medicaid Expansion Decisions: Interactive Map. Medicaid (Updated Nov 02, 2020)."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib25","unstructured":"Henry J. Kaiser Family Foundation, 2021. Opioid Overdose Death Rates and All Drug Overdose Death Rates per 100,000 Population (Age-Adjusted). Henry J. Kaiser Family Foundation Opioid Overdose Deaths: 1999\u20132018."},{"issue":"5","key":"10.1016\/j.drugalcdep.2021.109092_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2105\/AJPH.2020.306149","article-title":"The changing epidemiology of hepatitis C virus infection in the United States during the years 2010 to 2018","volume":"111","author":"Holtzman","year":"2020","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib27","series-title":"Applied Logistic Regression","author":"Hosmer","year":"2013"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib28","unstructured":"Howard, D., 2019. Effective Treatment of Opioid Use Disorder among African Americans, Effective Prevention and Treatment of Substance Use Disorders for Racial and Ethnic Minorties. IntechOpen."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib29","unstructured":"Howard, J., Solan, M., Neptune, J., Mellgren, L., Budenitz, J., Avery, K., 2016. The importance of Medicaid coverage for criminal justice involved individuals reentering into their communities. ASPE Issue Brief Department of Health and Human Services (April 2016)."},{"issue":"8","key":"10.1016\/j.drugalcdep.2021.109092_bib30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jvh.12684","article-title":"Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study","volume":"24","author":"Janjua","year":"2017","journal-title":"J. Viral Hepat"},{"issue":"8","key":"10.1016\/j.drugalcdep.2021.109092_bib31","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am. J. Public Health"},{"issue":"9","key":"10.1016\/j.drugalcdep.2021.109092_bib32","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib33","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.drugalcdep.2021.109092_bib34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/cid\/ciw869","article-title":"Geographic differences in temporal incidence trends of Hepatitis C Virus infection among people who inject drugs: the InC3 Collaboration","volume":"64","author":"Morris","year":"2017","journal-title":"Clin. Infect. Dis"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib35","unstructured":"National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation, 2021. Hepatitis C: State of Medicaid Access. Accessed on June 29, 2021. Retrieved from \u3008\u3008https:\/\/stateofhepc.org\/\u3009\u3009."},{"issue":"6","key":"10.1016\/j.drugalcdep.2021.109092_bib36","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s10597-020-00719-z","article-title":"The role of state Medicaid expansions in integrating comprehensive mental health services into opioid treatment programs: differences across the rural\/urban continuum","volume":"57","author":"Pro","year":"2020","journal-title":"Community Ment. Health J."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107952","article-title":"Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race\/ethnicity and gender, and year","volume":"209","author":"Pro","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11904-018-0396-x","article-title":"Integrated models of care for individuals with opioid use disorder: How do we prevent HIV and HCV","volume":"15","author":"Rich","year":"2018","journal-title":"Curr. HIV\/AIDS Rep"},{"issue":"8","key":"10.1016\/j.drugalcdep.2021.109092_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.6371","article-title":"Prevalence of hepatitis C virus infection in US States and the District of Columbia, 2013 to 2016","volume":"1","author":"Rosenberg","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib40","series-title":"Implications of the ACA Medicaid Expansion: a Look at the Data and Evidence","author":"Rudowitz","year":"2018"},{"issue":"4","key":"10.1016\/j.drugalcdep.2021.109092_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1588","article-title":"Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid Expansion","volume":"1","author":"Saloner","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib42","series-title":"The GLIMMIX Procedure","author":"SAS\/STAT, Inc","year":"2020"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib43","unstructured":"SAS\/STAT, Inc,Cary, NC, USA. SAS Institute, Inc."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults - United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR. Recommend. Rep."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11904-018-0393-0","article-title":"Challenges facing a rural opioid epidemic: treatment and prevention of HIV and Hepatitis C","volume":"15","author":"Schranz","year":"2018","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"5","key":"10.1016\/j.drugalcdep.2021.109092_bib46","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009","volume":"103","author":"Schwartz","year":"2013","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib47","series-title":"National Survey of Substance Abuse Treatment Services (N-SSATS): 2000. Data on Substance Abuse Treatment Facilities","author":"Substance Abuse and Mental Health Services Administration","year":"2002"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib48","series-title":"National Survey of Substance Abuse Treatment Services (N-SSATS): 2019 Data on Substance Abuse Treatment Facilities","author":"Substance Abuse and Mental Health Services Administration","year":"2020"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib49","series-title":"National Survey of Substance Abuse Treatment Services (N-SSATS): 2019","author":"Substance Abuse and Mental Health Services Administration","year":"2020"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib50","series-title":"Certification of Opioid Treatment Programs (OTPs)","author":"Substance Abuse and Mental Health Services Administration","year":"2021"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib51","article-title":"What\u2019s MAT got to do with it? Medication-assisted treatment for opioid use disorder in rural Aerica. Rural Health Information Hub","author":"Temple","year":"2018","journal-title":"Rural Monitor"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib52","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.drugalcdep.2021.109092_bib53","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatent","volume":"55","author":"Wen","year":"2017","journal-title":"Med. Care"},{"key":"10.1016\/j.drugalcdep.2021.109092_bib54","unstructured":"World Health Organization, 2016. Combating hepatitis B and C to reach elimination by 2013: Advocacy brief. Hepatitis (May 2016)."},{"key":"10.1016\/j.drugalcdep.2021.109092_bib55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40352-017-0047-0","article-title":"Commentary: the importance of Medicaid expansion for criminal justice populations in the south","volume":"5","author":"Zaller","year":"2017","journal-title":"Health Just."},{"issue":"2","key":"10.1016\/j.drugalcdep.2021.109092_bib56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to growing opioid epidemic and associated injection drug use","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871621005871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871621005871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:15:36Z","timestamp":1759828536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871621005871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":56,"alternative-id":["S0376871621005871"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109092","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109092"}}